Figure 17.

Inhibition of FGFR4 aggravated liver injury in Atg5^Δhepmice. (A) Scheme of treatment with FGFR4 inhibitor, Blu-9931 (BLU). Solvent (0.5% methylcellulose/1% Tween 80) was given as control. (B) Hepatic expression of indicated genes was analyzed by qRT-PCR (n = 4–7/group). (C) TBA levels in indicated compartments were measured (n = 6–8/group). (D) Ileal expression of indicated genes was analyzed by qRT-PCR (n = 4–6/group). (E) Serum levels of ALT, AST, ALP, and TBA in mice after BLU treatment (n = 6–8/group). (F) Liver sections were subjected to H&E, anti-CK19, or Masson’s trichrome staining. Percentage of positive area was quantified with ImageJ (CK19 staining quantification, n = 3–6/group; Masson’s trichrome staining quantification, n = 4–5/group). Data are shown as means ± SE. Groups with different lowercase letters had significant differences (P < .05). Bsep (Abcb11), bile salt export pump; N.S., no statistical significance.